MBC-11 (triethylamine)

MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC) . MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mbc-11-triethylamine.html

Purity

90.0

Solubility

10 mM in DMSO

Smiles

CCN(CC)CC.CC(P(O)(O)=O)(P(O)(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)=O)O

Molecular Formula

C17H35N4O14P3

Molecular Weight

612.40

References & Citations

[1]Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47 (1) :12-22.|[2]Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24 (3) :303-e102.